Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)UnknownNCT04681287
What this trial is testing

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Henan Cancer Hospital 46
Early research (Phase 1)Study completedNCT03945604
What this trial is testing

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Who this might be right for
Triple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 32
Testing effectiveness (Phase 2)Looking for participantsNCT07419464
What this trial is testing

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Who this might be right for
Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck
Washington University School of Medicine 46
Large-scale testing (Phase 3)Looking for participantsNCT07472153
What this trial is testing

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Who this might be right for
Metastatic Cervical CancerPersistent Cervical CancerRecurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre 120
Testing effectiveness (Phase 2)Study completedNCT03647839
What this trial is testing

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Australasian Gastro-Intestinal Trials Group 90
Testing effectiveness (Phase 2)UnknownNCT05990231
What this trial is testing

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Who this might be right for
Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 35
Testing effectiveness (Phase 2)Looking for participantsNCT03886311
What this trial is testing

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Who this might be right for
Sarcoma
Sarcoma Oncology Research Center, LLC 200
Early research (Phase 1)UnknownNCT03966209
What this trial is testing

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Who this might be right for
Hepatocellular CarcinomaLiver Transplantation
Shanghai Zhongshan Hospital 20
Not applicableStudy completedNCT05489692
What this trial is testing

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma
Sun Yat-sen University 43
Not applicableLooking for participantsNCT07401199
What this trial is testing

Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)

Who this might be right for
Gastric Cancer (GC)Locally Advanced Gastric Cancer
Qun Zhao 2,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06196671
What this trial is testing

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Fudan University 30
Testing effectiveness (Phase 2)Study completedNCT06501378
What this trial is testing

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

Who this might be right for
NSCLC Stage IV
Fudan University 40
Testing effectiveness (Phase 2)UnknownNCT06156878
What this trial is testing

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Who this might be right for
Nasopharyngeal Carcinoma
Fudan University 41
Testing effectiveness (Phase 2)Looking for participantsNCT07495215
What this trial is testing

A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

Who this might be right for
Hepatocellular Carcinoma (HCC)
Yinghua Xu 20
Not applicableLooking for participantsNCT06158919
What this trial is testing

PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Who this might be right for
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University 58
Testing effectiveness (Phase 2)Looking for participantsNCT04785196
What this trial is testing

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Who this might be right for
LiposarcomaAdvanced Solid Tumor
Ascentage Pharma Group Inc. 95
Testing effectiveness (Phase 2)UnknownNCT05724355
What this trial is testing

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Who this might be right for
Nasopharyngeal Carcinoma
Sun Yat-sen University 32
Testing effectiveness (Phase 2)Looking for participantsNCT07644286
What this trial is testing

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Who this might be right for
Colorectal Cancer (CRC)
Tao Zhang 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06980389
What this trial is testing

Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)

Who this might be right for
Immune Checkpoint TherapyRadiotherapyMetastatic Gastric Carcinoma
Sixth Affiliated Hospital, Sun Yat-sen University 176
Next Page